AECOM just delivered one of its worst weeks in years — a 17% share-price collapse that left the stock near $69.95 and sent the Street scrambling to reprice.
The trigger was clear. AECOM reported Q2 earnings after the close on May 11, and the market's verdict was brutal: the stock fell 13.2% on May 12, a single-day move that has defined the week. The drop erased months of gains and pushed the share price to levels not seen in some time, compressing valuation multiples sharply across the board. EV/EBITDA fell roughly a full turn over the week to 8.2x, and the P/E ratio dropped to 11.2x. At that level, the stock trades at a meaningful discount to the historical range implied by prior analyst targets.
The clearest read on positioning sits in options. Call-side demand dramatically outstripped puts on the day of the earnings print — the put/call ratio crashed to 0.40 on May 12, nearly 3.7 standard deviations below its 20-day mean of 0.47. That's the lowest PCR reading of the year and sits near the 52-week floor of 0.27. The interpretation is that traders rushed to buy calls into or just after the selloff, either as a hedge against short positions or as opportunistic bets on a bounce. Either way, the options market is not positioned defensively — it has tilted sharply bullish following the drop.
Short interest tells a more measured story. At roughly 4.6% of the free float, the short base is real but not extreme — it eased about 7.5% over the week, from close to 5.2% to 4.6%, as some shorts covered into the decline. Borrowing costs remain minimal at 0.42% annualised, and availability in the lending market is wide, meaning there is no mechanical squeeze pressure on the short side. The short score has also edged lower, from around 42 a week ago to 40.9 — still in the middle of its range, signalling no acute crowding.
The Street's response to the earnings miss was swift and unanimous in direction. Citigroup's Andrew Kaplowitz — who lowered his target from $130 to $98 just today while holding a Buy — made the most aggressive cut. RBC Capital dropped its Outperform target from $142 to $111 on the same day, and Truist cut to $109 from $116. Keybanc moved its Overweight target from $115 to $101. All four kept positive ratings despite the significant downward revisions. Baird, the lone Neutral voice, cut from $98 to $91 on May 12. The mean consensus target now rests at $111, still implying close to 60% upside from the current price — a gap that reflects the speed of the selloff more than confident street consensus. Bulls point to AECOM's structural growth story: Adjusted EBITDA has nearly doubled since 2019 at an ~11% CAGR, and margins expanded by nearly 500 basis points. Bears focus on the company's heavy reliance on government contracts, which makes it vulnerable to budget tightening, and the potential for further margin disappointments when execution misses.
Among factor scores, the dividend profile ranks at the 92nd percentile and EV/EBIT sits at the 85th percentile of the universe — signals that at current prices, the value argument is becoming more compelling, at least relative to the stock's history. Forward EPS growth (12-month YoY) scores at the 75th percentile, suggesting the earnings base is still expected to grow. Near-term EPS momentum, at the 38th percentile over 30 days, has deteriorated noticeably following the print. Correlated peers STN and WSP also fell hard on the week, down 9.1% and 9.6% respectively, confirming the move is at least partly sector-wide rather than purely AECOM-specific — though ACM's 17% drop is roughly double the peer decline.
The next question is whether the rapid analyst target resets — most coming through today and yesterday — are enough to reprice expectations, or whether further estimate cuts follow as management guidance is absorbed. The gap between the current $70 share price and a mean target of $111 will test whether buyers treat this as a value entry or a falling knife.
See the live data behind this article on ORTEX.
Open ACM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
